Clinical Trials

Checkmate Pharmaceuticals is investigating the efficacy and safety of vidutolimod (CMP-001) in combination with checkpoint inhibitors in patients with various types of cancer, including melanoma and head and neck. To learn more about vidutolimod, a virus-like particle containing a CpG-A TLR9 agonist, visit our Science page.

We are recruiting eligible patients to participate in our ongoing immuno-oncology clinical trials with vidutolimod. For more information on our trials, please view the pages below or contact us at clinicaltrials@checkmatepharma.com.

Now Enrolling

Current Clinical Trials

Melanoma

CMP-001-010: Advanced Refractory Melanoma

A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma

CMP-001-011: First-line Melanoma

A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

CMP-001-007: First-line HNSCC

A Multicenter, Phase 2, Open-label Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Physicians: For details on clinical trial eligibility criteria, site locations and contacts, please visit clinicaltrials.gov.

Scroll to Top